Literature DB >> 28758834

Preferential interactions of trehalose, L-arginine.HCl and sodium chloride with therapeutically relevant IgG1 monoclonal antibodies.

Chaitanya Sudrik1, Theresa Cloutier1, Phuong Pham1, Hardeep S Samra2, Bernhardt L Trout1.   

Abstract

Preferential interactions of weakly interacting formulation excipients govern their effect on the equilibrium and kinetics of several reactions of protein molecules in solution. Using vapor pressure osmometry, we characterized the preferential interactions of commonly used excipients trehalose, L-arginine.HCl and NaCl with three therapeutically-relevant, IgG1 monoclonal antibodies that have similar size and shape, but differ in their surface hydrophobicity and net charge. We further characterized the effect of these excipients on the reversible self-association, aggregation and viscosity behavior of these antibody molecules. We report that trehalose, L-arginine.HCl and NaCl are all excluded from the surface of the three IgG1 monoclonal antibodies, and that the exclusion behavior is linearly related to the excipient molality in the case of trehalose and NaCl, whereas a non-linear behavior is observed for L-arginine.HCl. Interestingly, we find that the magnitude of trehalose exclusion depends upon the nature of the protein surface. Such behavior is not observed in case of NaCl and L-arginine.HCl as they are excluded to the same extent from the surface of all three antibody molecules tested in this study. Analysis of data presented in this study provides further insight into the mechanisms governing excipient-mediated stabilization of mAb formulations.

Entities:  

Keywords:  L-arginine.HCl; Trehalose; mAb stability; preferential exclusion; preferential hydration; sodium chloride; therapeutic monoclonal antibody formulation; vapor pressure osmometry

Mesh:

Substances:

Year:  2017        PMID: 28758834      PMCID: PMC5627590          DOI: 10.1080/19420862.2017.1358328

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  55 in total

1.  Construction, MD simulation, and hydrodynamic validation of an all-atom model of a monoclonal IgG antibody.

Authors:  J Paul Brandt; Thomas W Patapoff; Sergio R Aragon
Journal:  Biophys J       Date:  2010-08-04       Impact factor: 4.033

Review 2.  Monoclonal antibody therapy of cancer.

Authors:  Gregory P Adams; Louis M Weiner
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

Review 3.  Accelerated formulation development of monoclonal antibodies (mAbs) and mAb-based modalities: review of methods and tools.

Authors:  Vladimir I Razinkov; Michael J Treuheit; Gerald W Becker
Journal:  J Biomol Screen       Date:  2015-01-09

Review 4.  Subcutaneous Injection Volume of Biopharmaceuticals-Pushing the Boundaries.

Authors:  Roman Mathaes; Atanas Koulov; Susanne Joerg; Hanns-Christian Mahler
Journal:  J Pharm Sci       Date:  2016-07-01       Impact factor: 3.534

5.  Abnormal solubility behavior of beta-lactoglobulin: salting-in by glycine and NaCl.

Authors:  T Arakawa; S N Timasheff
Journal:  Biochemistry       Date:  1987-08-11       Impact factor: 3.162

Review 6.  Therapeutic protein aggregation: mechanisms, design, and control.

Authors:  Christopher J Roberts
Journal:  Trends Biotechnol       Date:  2014-06-04       Impact factor: 19.536

7.  Specific ion and buffer effects on protein-protein interactions of a monoclonal antibody.

Authors:  D Roberts; R Keeling; M Tracka; C F van der Walle; S Uddin; J Warwicker; R Curtis
Journal:  Mol Pharm       Date:  2014-12-02       Impact factor: 4.939

8.  Preferential interactions of proteins with salts in concentrated solutions.

Authors:  T Arakawa; S N Timasheff
Journal:  Biochemistry       Date:  1982-12-07       Impact factor: 3.162

9.  RosettaAntibody: antibody variable region homology modeling server.

Authors:  Aroop Sircar; Eric T Kim; Jeffrey J Gray
Journal:  Nucleic Acids Res       Date:  2009-05-20       Impact factor: 16.971

Review 10.  Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases.

Authors:  Michela Flego; Alessandro Ascione; Maurizio Cianfriglia; Stefano Vella
Journal:  BMC Med       Date:  2013-01-04       Impact factor: 8.775

View more
  5 in total

1.  Isotonic concentrations of excipients control the dimerization rate of a therapeutic immunoglobulin G1 antibody during refrigerated storage based on their rank order of native-state interaction.

Authors:  Douglas D Banks; Jon F Cordia; Vladimir Spasojevic; Jeonghoon Sun; Sarah Franc; Younhee Cho
Journal:  Protein Sci       Date:  2018-12       Impact factor: 6.725

2.  Understanding the Role of Preferential Exclusion of Sugars and Polyols from Native State IgG1 Monoclonal Antibodies and its Effect on Aggregation and Reversible Self-Association.

Authors:  Chaitanya M Sudrik; Theresa Cloutier; Neil Mody; Hasige A Sathish; Bernhardt L Trout
Journal:  Pharm Res       Date:  2019-05-24       Impact factor: 4.200

3.  Trehalose Inhibits the Heat-Induced Formation of the Amyloid-Like Structure of Soluble Proteins Isolated from Human Cataract Lens.

Authors:  Lakshman Ram; Chandrika Mittal; Ram Swaroop Harsolia; Jay Kant Yadav
Journal:  Protein J       Date:  2020-10-10       Impact factor: 2.371

4.  Dissecting the molecular basis of high viscosity of monospecific and bispecific IgG antibodies.

Authors:  Cholpon Tilegenova; Saeed Izadi; Jianping Yin; Christine S Huang; Jiansheng Wu; Diego Ellerman; Sarah G Hymowitz; Benjamin Walters; Cleo Salisbury; Paul J Carter
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

5.  Molecular computations of preferential interactions of proline, arginine.HCl, and NaCl with IgG1 antibodies and their impact on aggregation and viscosity.

Authors:  Theresa K Cloutier; Chaitanya Sudrik; Neil Mody; Sathish A Hasige; Bernhardt L Trout
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.